Xeris Biopharma (NASDAQ:XERS) Price Target Raised to $6.00

Xeris Biopharma (NASDAQ:XERS) had its price target hoisted by Leerink Partners from $5.00 to $6.00 in a research report report published on Friday,Benzinga reports. They currently have an outperform rating on the stock.

A number of other equities analysts have also recently commented on the company. Jefferies Financial Group restated a “buy” rating and set a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Piper Sandler reissued a “neutral” rating and set a $4.00 target price (up from $3.00) on shares of Xeris Biopharma in a research note on Friday. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a research note on Friday. Finally, Craig Hallum upped their target price on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a research note on Friday. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $5.92.

Xeris Biopharma Trading Up 0.4 %

XERS stock traded up $0.02 during midday trading on Friday, hitting $4.26. 793,105 shares of the company’s stock were exchanged, compared to its average volume of 1,912,517. Xeris Biopharma has a 1-year low of $1.69 and a 1-year high of $4.50. The business has a 50-day simple moving average of $3.57 and a two-hundred day simple moving average of $3.26. The stock has a market capitalization of $634.34 million, a PE ratio of -9.41 and a beta of 2.32.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Xeris Biopharma by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company’s stock worth $26,778,000 after buying an additional 133,738 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Xeris Biopharma by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 3,351,426 shares of the company’s stock worth $11,364,000 after purchasing an additional 17,956 shares during the period. AIGH Capital Management LLC grew its position in Xeris Biopharma by 17.8% in the 4th quarter. AIGH Capital Management LLC now owns 2,574,846 shares of the company’s stock valued at $8,729,000 after buying an additional 389,192 shares during the last quarter. Renaissance Technologies LLC grew its position in Xeris Biopharma by 31.3% in the 4th quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company’s stock valued at $7,115,000 after buying an additional 500,120 shares during the last quarter. Finally, Millennium Management LLC increased its stake in Xeris Biopharma by 34.8% in the 4th quarter. Millennium Management LLC now owns 1,948,552 shares of the company’s stock valued at $6,606,000 after buying an additional 502,853 shares during the period. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.